|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
CD52 antigen Protein Datasheet
CD52 / CDW52 Protein Price Inquiry ( Available Sizes )
CD52 / CDW52 Protein Product Information
|Synonym :||CD52, Cdw52, Rb7|
A DNA sequence encoding the rat ILCD52 (Q63064) (Met1-Ala69) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
|Expression Host:||Human Cells|
CD52 / CDW52 Protein QC Testing
|Purity:||> 70 % as determined by SDS-PAGE||SDS-PAGE:
CD52 / CDW52 protein
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||Gly 24|
The recombinant rat CD52/Fc is a disulfide-linked homodimer. The reduced monomer comprises 287 amino acids and has a predicted molecular mass of 31.4 kDa. The apparent molecular mass of the protein is approximately 53 kDa in SDS-PAGE under reducing conditions.
|Formulation:||Lyophilized from sterile PBS, pH7.4.
CD52 / CDW52 Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
CD52 / CDW52 Protein Related Products & Topics
CD52 / CDW52 Protein Description
CDw52 is a small glycosylphosphatidylinositol (GPI) anchored glycoprotein. It has a mature peptide comprising only 12 amino acids and is abundantly expressed on human lymphocytes. It is also expressed at a high level in the male reproductive system, being found in the epididymis, seminal vesicle, seminal plasma and on the surface of mature (but not testicular) spermatozoa. Its possible transfer from epithelial cells in the epididymis to maturing sperm may represent a novel method of acquisition of cell surface antigens. CDw52 may play a role in carrying and orienting carbohydrate. It is an unusually good target for complement-mediated cell lysis. CDw52 is targeted by alemtuzumab which is an antibody used for the treatment of chronic lymphocytic leukemia and currently being evaluated in a phase III clinical trial for the treatment of multiple sclerosis.
- Buggins AG. et al., 2002, Blood. 100 (5): 1715-20.
- Ratzinger G. et al., 2003, Blood. 101 (4): 1422-9.
- Piccaluga PP. et al., 2007, Haematologica. 92 (4): 566-7.